메뉴 건너뛰기
The Lancet Oncology
Volumn 10, Issue 12, 2009, Pages 1140-1141
Cetuximab and panitumumab: are they interchangeable?
Author keywords

[No Author keywords available]
Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;
EID: 71449090449     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70312-2     Document Type: Letter
Times cited : (17)
References (6)
  • 1
    • 71449100773 scopus 로고    scopus 로고
    • A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): results according to KRAS and BRAF mutation status
    • Van Cutsem E., Köhne C., Stroh C., et al. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): results according to KRAS and BRAF mutation status. European J Cancer Supp 7 (2009) 345
    • (2009) European J Cancer Supp , vol.7 , pp. 345
    • Van Cutsem, E.1    Köhne, C.2    Stroh, C.3
  • 2
    • 51649120733 scopus 로고    scopus 로고
    • KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience
    • abstr 4000.
    • Bokemeyer C., Bondarenko I., Hartmann J.T., et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. Proc Am Soc Clin Oncol 26 suppl (2008) abstr 4000.
    • (2008) Proc Am Soc Clin Oncol , vol.26 , Issue.SUPPL
    • Bokemeyer, C.1    Bondarenko, I.2    Hartmann, J.T.3
  • 3
    • 59749091477 scopus 로고    scopus 로고
    • Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
    • Tol J., Koopman M., Cats A., et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360 (2009) 563-572
    • (2009) N Engl J Med , vol.360 , pp. 563-572
    • Tol, J.1    Koopman, M.2    Cats, A.3
  • 4
    • 71449087289 scopus 로고    scopus 로고
    • Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)
    • Adams R.W., Seymour M.T., Meade A.M., et al. Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN). European J Cancer Supp 7 (2009) 10
    • (2009) European J Cancer Supp , vol.7 , pp. 10
    • Adams, R.W.1    Seymour, M.T.2    Meade, A.M.3
  • 5
    • 59949102930 scopus 로고    scopus 로고
    • A randomized phase 3B trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer
    • Hecht J.R., Mitchell E., Chidiac T., et al. A randomized phase 3B trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 27 (2009) 672-680
    • (2009) J Clin Oncol , vol.27 , pp. 672-680
    • Hecht, J.R.1    Mitchell, E.2    Chidiac, T.3
  • 6
    • 71249136106 scopus 로고    scopus 로고
    • Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial
    • Douillard J.S., Cassidy J., Tabernero J., et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. European J Cancer Supp 7 (2009) 6
    • (2009) European J Cancer Supp , vol.7 , pp. 6
    • Douillard, J.S.1    Cassidy, J.2    Tabernero, J.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.